- Home
- AGEN vs JVSA Comparison
AGEN vs JVSA Comparison
Compare AGEN & JVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- JVSA
- Stock Information
- Founded
- AGEN 1994
- JVSA 2021
- Country
- AGEN United States
- JVSA Hong Kong
- Employees
- AGEN N/A
- JVSA N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- JVSA
- Sector
- AGEN Health Care
- JVSA
- Exchange
- AGEN Nasdaq
- JVSA NYSE
- Market Cap
- AGEN 87.7M
- JVSA 82.7M
- IPO Year
- AGEN 2000
- JVSA 2024
- Fundamental
- Price
- AGEN $5.16
- JVSA $10.85
- Analyst Decision
- AGEN Buy
- JVSA
- Analyst Count
- AGEN 4
- JVSA 0
- Target Price
- AGEN $13.00
- JVSA N/A
- AVG Volume (30 Days)
- AGEN 1.6M
- JVSA 68.6K
- Earning Date
- AGEN 08-07-2025
- JVSA 01-01-0001
- Dividend Yield
- AGEN N/A
- JVSA N/A
- EPS Growth
- AGEN N/A
- JVSA 719.53
- EPS
- AGEN N/A
- JVSA 0.27
- Revenue
- AGEN $99,524,000.00
- JVSA N/A
- Revenue This Year
- AGEN $14.49
- JVSA N/A
- Revenue Next Year
- AGEN N/A
- JVSA N/A
- P/E Ratio
- AGEN N/A
- JVSA $39.96
- Revenue Growth
- AGEN N/A
- JVSA N/A
- 52 Week Low
- AGEN $1.38
- JVSA $10.13
- 52 Week High
- AGEN $18.74
- JVSA $11.91
- Technical
- Relative Strength Index (RSI)
- AGEN 62.39
- JVSA N/A
- Support Level
- AGEN $5.06
- JVSA N/A
- Resistance Level
- AGEN $6.35
- JVSA N/A
- Average True Range (ATR)
- AGEN 0.59
- JVSA 0.00
- MACD
- AGEN 0.12
- JVSA 0.00
- Stochastic Oscillator
- AGEN 65.00
- JVSA 0.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About JVSA JVSPAC ACQUISITION CORP
JVSPAC Acquisition Corp is blank check company.